{"data":{"responsecode":"000","responsemsg":"","quote":{"hi":"5.390","rs_stock_flag":false,"fiscal_year_end":"2024年12月31日","hist_closedate":"2025年9月25日","replication_method":null,"amt_os":"220,094,500","primaryexch":"香港交易所","ric":"9989.HK","product_subtype":null,"db_updatetime":"2025年9月28日08:06","mkt_cap_u":"B","am_u":"M","ew_sub_right":"","secondary_listing":false,"ew_amt_os_cur":null,"ccy":"HKD","management_fee":"","ew_underlying_code":null,"trdstatus":"N","nav":"","original_offer_price":"","issue":"","asset_class":null,"eps":0.4408,"inline_upper_strike_price":"","sedol":"BMFR225","am":"13.58","iv":"","ew_strike":"","as":"5.310","geographic_focus":null,"incorpin":"中華人民共和國","etp_baseCur":null,"ew_amt_os":"","bd":"5.300","registrar":"卓佳證券登記有限公司","depositary":null,"exotic_type":null,"callput_indicator":null,"primary_market":null,"underlying_index":null,"lot":"500","update_time":"2025-09-28 00:06:03.0","lo52":"3.200","shares_issued_date":"2025年8月31日","premium":"","strike_price_ccy":null,"yield":"","vo_u":"M","base_currency":null,"coupon":"","expiry_date":"","chairman":"李鋰","underlying_ric":"002399.SZ","hi52":"7.260","issuer_name":"深圳市海普瑞藥業集團股份有限公司 - H股","h_share_flag":true,"ew_sub_per_from":"","div_yield":"5.12","interest_payment_date":"-","updatetime":"2025年9月26日16:08","aum_date":"","lo":"5.290","mkt_cap":"1.16","f_aum_hkd":null,"ew_sub_per_to":"","ls":"5.310","nav_date":"","csic_classification":"醫藥衛生","floating_flag":false,"issued_shares_note":null,"nom_ccy":null,"eff_gear":"","board_lot_nominal":null,"hsic_ind_classification":"醫療保健業 - 藥品及生物科技","ew_desc":null,"inception_date":"","nc":"-0.080","aum":"","issued_shares_class_B":null,"vo":"2.55","secondary_listing_flag":false,"listing_date":"2020年7月8日","issued_shares_class_A":null,"as_at_label":"截至","ew_amt_os_dat":"","nm":"深圳市海普瑞藥業集團股份有限公司 - H股","nm_s":"海普瑞","sym":"9989","inline_lower_strike_price":"","listing_category":"主要上市","ew_strike_cur":null,"exotic_warrant_indicator":null,"investment_focus":null,"call_price":"","tck":"0.010","strike_price":"","summary":"深圳市海普瑞藥業集團股份有限公司是一家中國製藥公司，在肝素鈉製劑及原料藥領域、大分子藥物合同開發和生產組織(CDMO)領域以及創新藥開發領域擁有業務。該公司主要產品和服務包括依諾肝素鈉製劑和肝素鈉原料藥、依諾肝素鈉原料藥，以及大分子藥物CDMO服務。該公司的產品在國內市場和包括土耳其、巴西、美國等在內的海外市場銷售。","op":"5.360","aum_u":"","nav_ccy":null,"class_B_description":null,"os":"","wnt_gear":"","transfer_of_listing_date":"","hsic_sub_sector_classification":"藥品","amt_ccy":null,"class_A_description":null,"domicile_country":null,"entitlement_ratio":"","product_type":"EQTY","office_address":"中國<br/>深圳市<br/>南山區<br/>郎山路21號","pc":"-1.48","days_to_expiry":null,"underlying_code":null,"pe":"11.39","eps_ccy":"RMB","hdr":false,"launch_date":"","hc":"5.390","isin":"CNE100003YN2","moneyness":""}},"qid":"1759074357700"}
